about
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic CeAdverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis.Multiple myeloma: routes to diagnosis, clinical characteristics and survival - findings from a UK population-based study.A molecular diagnostic approach able to detect the recurrent genetic prognostic factors typical of presenting myelomaMinimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reductionTrends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years.APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myelomaHigh-dose therapy and autologous stem cell transplantation in patients with POEMS syndrome: a retrospective study of the Plasma Cell Disorder sub-committee of the Chronic Malignancy Working Party of the European Society for Blood & Marrow TransplantRecommendations for a standard UK approach to incorporating umbilical cord blood into clinical transplantation practice: an update on cord blood unit selection, donor selection algorithms and conditioning protocols.Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients.Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma.Downregulation of myeloma-induced ICOS-L and regulatory T cell generation by lenalidomide and dexamethasone therapy.Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial.Treatment options for relapse after autograft in multiple myeloma - report from an EBMT educational meeting.Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.The "Next Big Thing" in Treatment for Relapsed or Refractory Multiple Myeloma May Be Held Back by Design-Between the Lines.Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial.Autologous Stem Cell Transplantation Is an Effective Salvage Therapy for Primary Refractory Multiple Myeloma.Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen.United Kingdom Myeloma Forum position statement on the use of consolidation and maintenance treatment in myeloma.A retrospective multi-centre study of the effects of allogeneic haematopoietic SCT on pulmonary function.Unrelated Cord Blood Transplantation in adults: evolution, experience and long-term outcomes in the UK National Health Service : a retrospective analysis on behalf of the British Society of Blood and Marrow Transplantation and Eurocord.Time to redefine Myeloma.Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood and Marrow Transplantation/United Kingdom Myeloma Forum Myeloma X (Intensive) Trial.Re-invigorating rather than re-inventing the wheel: augmenting the impact of salvage autologous stem cell transplantation for multiple myeloma in the era of novel agents.Optimizing the management of patients with spinal myeloma disease.Carmustine, etoposide, cytarabine, and melphalan (BEAM)-campath allogeneic stem cell transplantation for aggressive non-hodgkin lymphoma: an analysis of outcomes from the British Society of Blood and Marrow Transplantation.Impact of pre-transplant co-morbidities on outcome after alemtuzumab-based reduced intensity conditioning allo-SCT in elderly patients: a British Society of Blood and Marrow Transplantation study.The impact of total body irradiation on the outcome of patients with follicular lymphoma treated with autologous stem-cell transplantation in the modern era: a retrospective study of the EBMT Lymphoma Working Party.Updates to the guidelines for the diagnosis and management of multiple myelomaOsteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study resultsDaratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 studyReal-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with Multiple Myeloma receiving systemic anti-cancer therapyDefining the vulnerable patient with myeloma-a frailty position paper of the European Myeloma Network
P50
Q26782868-69EFF3CB-E63C-466D-BD00-1CB394B1B289Q33441845-915BE94A-8CE1-47E4-A37E-6D82ECDCFDFCQ33578273-4E139832-DACE-4D54-9B81-1894F0B98296Q35025456-201E287C-F7AD-4B4E-950A-DFD4395EDBE1Q35222117-0723BC0C-6069-4F09-B285-78A20189682CQ35410550-0596DF38-7514-475D-8318-10DF578420BEQ36055752-A52C036F-BDE0-4D4B-B2D3-24FFAD40E32AQ37555831-C49ECC55-D56D-4ECC-BA9A-E661A034559BQ38636111-2F7E7FBD-642B-41C9-92E6-627471413E53Q38742055-6F8E12B4-7837-41B3-B761-EC75DD3F2A6BQ38817467-215026CC-0F96-4A6C-A1F3-F9719E1D94DCQ38866579-AB831D83-81A9-47B0-9F80-BD2CDE2922AAQ39034157-EC15F005-4A9E-4FCB-B38A-FB355C7EA72DQ39369772-4BADC223-D762-4C18-9AA9-8A9F4ACA020BQ40633414-BC631258-92F6-4D6D-B1BD-F476225D4A80Q40669032-C01B93D4-7B36-42CE-8721-0C0B281DEC23Q40676209-53B0CBDF-D7C3-45E5-8772-EDF97548F8D9Q41044036-9FC288CA-8D3B-4B59-824F-57A78DE309A4Q41113942-DCC3F8ED-B268-442C-882B-1EA1453655D2Q42427616-7A57EFA4-DCBB-4143-9101-5D58B3DAE422Q46779037-1E12A8F6-9700-434D-91F7-4B7D37531CA6Q46921945-AC9F0F3C-8DF5-4C68-A585-3F95279246F1Q47569026-CE57BE5D-E454-4A1E-8EA8-11C0097C6056Q48971392-E328179E-47BF-4D18-9424-4C541766F081Q52812971-7C9ADCEB-33FE-46F0-AB40-3F8B5F7ED9BBQ52818331-A0672FB1-F551-4834-AFCD-14B0AD247362Q52836468-6B67D1AB-621F-4C2D-90D0-8CB383400128Q52836567-37AC1737-B7AA-4E90-9E0D-B7D517EA581CQ52838213-D99653A8-68E7-4105-BBBD-A2CFAC33CA64Q52838715-0D6EA86E-0787-4F20-A12D-2DF760098265Q52838931-FDC4C87B-BD6E-40C7-A59E-9616E75B6632Q58417652-E800708F-2A74-4496-8DCA-7ED42D7B67FBQ58417653-3606F2AC-E9FB-4078-9B06-8A8F0282534CQ89455190-4EB7ECEE-A9A4-4A54-AE4D-15335EF4E536Q95636593-BB77ED30-D9AF-4B72-89EF-239D1CB20EEDQ96576748-F7BD5237-4904-404B-AD46-D8F111582EC9
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Gordon Cook
@ast
Gordon Cook
@en
Gordon Cook
@es
Gordon Cook
@nl
Gordon Cook
@sl
غوردون كوك
@ar
type
label
Gordon Cook
@ast
Gordon Cook
@en
Gordon Cook
@es
Gordon Cook
@nl
Gordon Cook
@sl
غوردون كوك
@ar
prefLabel
Gordon Cook
@ast
Gordon Cook
@en
Gordon Cook
@es
Gordon Cook
@nl
Gordon Cook
@sl
غوردون كوك
@ar
P214
P106
P21
P214
P31
P496
0000-0003-1717-0412
P734
P735
P7859
viaf-309717280